HOLX Price Prediction Next Week
Technical Analysis: HOLX is currently in a strong downtrend, with RSI at 27.10 indicating oversold conditions. The stock has broken below its key support levels and is trading significantly below all major moving averages (5-day: $64.02, 20-day: $68.97, 200-day: $76.63).
Price Target Analysis for Next Week: Based on Fibonacci levels and current technical setup:
- Support levels: $63.68 (S1), $61.28 (S2)
- Resistance levels: $71.41 (R1), $73.80 (R2)
News Impact:
- Recent Q1 results led to reduced FY25 revenue guidance due to currency headwinds and weakness in breast health capital sales
- Company maintained EPS guidance despite revenue challenges, showing strong profitability management
- Multiple analysts have lowered their price targets, with RBC Capital reducing from $88 to $85
Price Prediction for Next Week: Given the current technical setup and news sentiment:
- Most likely scenario (60% probability): Further decline to test S1 level at $63.68
- Target range: $63.50-$64.50
- Key catalysts: Oversold conditions could trigger a minor technical bounce, but overall bearish momentum remains strong
Trading Recommendation: SELL
- Current oversold conditions suggest potential for short-term bounces, but the overall trend remains bearish
- Multiple analysts have downgraded the stock and lowered price targets
- Technical indicators show continued weakness with MACD at -2.33 and declining moving averages
- Recommended to wait for a potential bounce before initiating short positions
HOLX Similar Chart Price Prediction
The price of HOLX is predicted to go up 8.39%, based on the high correlation periods with HY. The similarity of these two price pattern on the periods is 97.7%.
HOLX
HY
Up: 8.39%Similarity: 97.7%
HOLX Revenue Forecast
HOLX EPS Forecast
HOLX FAQs
What is bull’s view on HOLX?
What is bear's view on HOLX?
What is HOLX revenue forecast for next quarter？
What is HOLX eps forecast for next quarter？
HOLX VS S&P500
Hologic was first to market with an FDA-approved 3D mammography platform in the U.S., giving it a considerable head start in its installed base against GE and Siemens.
Hologic controls the lion's share of the U.S. liquid-based Pap market, and the Gen-Probe acquisition catapulted the firm into number-one positions in testing for chlamydia and gonorrhea.
Over time, reimbursement for 3D mammography has become widespread in the U.S., and there is still room for this to grow outside the U.S.
HOLX Analyst's Forecast
Andrew Cooper
Raymond James
Buy
2025-02-06
Price Target
$95 → $90
Upside
+37.24%
Raymond James lowered the firm's price target on Hologic to $90 from $95 and keeps an Outperform rating on the shares. Hologic's print was essentially in line, but revenue guidance was cut as the breast health business required a reassessment both out of a bolus and ahead of a product update, the analyst tells investors in a research note. The firm says fiscal 2025 looks a "little more irregular" than was hoped as the breast health organization navigates a slower end market, and management must prove that these dynamics are a blip.
Andrew Cooper
Raymond James
Buy
2024-11-05
Price Target
$93 → $95
Upside
+20.56%
Anthony Petrone
Mizuho
Buy
2024-11-05
Price Target
$90 → $87
Upside
+10.41%
